MPD-RC 112 Clinical Trial for High Risk PV and ET Patients

Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea

Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET).

Key Points:  Why are we doing the Study?

Top Goal:  Which therapy (hydroxyurea or pegylated interferon alpha 2a (Pegasys) is more successful in achieving a complete response by LeukemiaNet Criteria

Other Key Goals:

  1. Partial response rate by Leukemia criteria
  2. Decrease JAK2-V617F Allele Burden
  3. Decrease Vascular Events (blood clots or bleeding)
  4. MPN Symptoms
  5. Tolerability of the therapy
  6. Progression of disease

Who-is-trial-for2

 

 

 

 

 

 

 

What-happens-on-the-trial2
 

 

 

 

Where-is-the-trial-open-US-sites2

About David Wallace

Founder of PV Reporter, a resource for Myeloproliferative Neoplasm (MPN) patients and caregivers. After being diagnosed with Polycythemia Vera (PV) in 2009, I utilized social media to connect with "informed patients" and develop a better understanding of emerging treatment options. My philosophy on patient care is straight forward - "educating the patient is essential, so the patient can guide their physician to meet his or her needs." PV Reporter is a comprehensive resource hub giving visitors vital tools to become "empowered patients."

error: Content is protected !
Malcare WordPress Security